Welcome to our dedicated page for Greater Cannabis news (Ticker: GCAN), a resource for investors and traders seeking the latest updates and insights on Greater Cannabis stock.
Greater Cannabis Company, Inc. (OTC: GCAN), also known as GCANRx, generates news primarily as a clinical stage biopharmaceutical company focused on cannabinoid therapeutics for neuropsychiatric disorders. News coverage often centers on its progress in developing a proprietary neuroprotective cannabinoid therapy, particularly for Autism Spectrum Disorder (ASD) and related conditions.
Readers following GCAN news can expect updates on preclinical and clinical milestones. The company has reported initiation and completion of preclinical studies that assessed anti-inflammatory, anti-oxidative and cytoprotective effects of its therapeutic in microglial cell models. It has also announced regulatory interactions and approvals, including submission of a Phase 2 clinical trial application to the Israel Ministry of Health and subsequent final approval for a double blind, placebo controlled Phase II trial in pediatric ASD patients.
GCANRx news also highlights its collaborations and scientific recognition. Releases have described its license and research agreement with Shaare Zedek Scientific, the role of Dr. Adi Aran as inventor and strategic advisor, and the involvement of Professor Tal Burstyn-Cohen’s laboratory through Yissum in preclinical work. The company has been featured in the American Journal of Endocannabinoid Medicine in the context of autism and cannabis research, and its scientific advisor has appeared in media coverage on cannabinoid therapies.
From a capital markets perspective, GCAN-related news includes corporate actions and trading status developments, such as a 1-for-1,500 reverse stock split and uplisting steps within the OTC market structure, including approval for quotation on the OTCQB Venture Market. The company has also issued updates on exploring strategic alternatives, mentioning interest from businesses in artificial intelligence and quantum computing.
This news page aggregates these types of announcements so investors and observers can review GCANRx’s research progress, regulatory events, collaborations and capital markets disclosures in one place.
Greater Cannabis Company (OTC: GCAN) announced that its common stock was approved for quotation on the OTCQB Venture Market effective December 3, 2025. To qualify, companies must meet higher financial and disclosure standards and follow best-practice corporate governance. The company says the move should provide enhanced investor benefits, including higher reporting standards, greater access to analyst coverage and news services, and more comprehensive compliance. The OTCQB is recognized by the SEC as an established public market for determining public market price for resale registrations.
U.S. investors can find current financial disclosure and Real-Time Level 2 quotes on otcmarkets.com. For investor inquiries visit gcanrx.com or contact info@gcanrx.com.
Greater Cannabis Company (OTC: GCAN) has received approval for its application to uplist to the OTCID Basic Market, effective July 1, 2025. The biopharmaceutical company, focused on developing next-generation cannabinoid therapeutics and consumer products, will transition to this new market tier which requires higher standards for transparency, compliance, and corporate governance.
According to CEO Aitan Zacharin, this uplisting validates the company's commitment to regulatory discipline and is expected to enhance visibility, liquidity, and transparency for shareholders through a more structured trading environment.
Greater Cannabis Company (OTC: GCAN) has announced its exploration of strategic alternatives in Artificial Intelligence and Quantum Computing sectors while maintaining its existing biopharmaceutical business. The company is evaluating various options including potential sale, merger, or strategic business combinations in response to interest from companies developing cutting-edge technologies.
CEO Aitan Zacharin indicated that multiple companies in these emerging technology sectors have approached GCAN expressing interest in potential mergers. The company emphasizes that while it's exploring these opportunities to maximize shareholder value, there's no guarantee that any transaction will be completed or that favorable terms will be achieved. No specific timeline has been set for completing this evaluation process.
Summary not available.
Summary not available.
Summary not available.
Greater Cannabis Company (GCAN) has submitted a clinical trial application to the Israel Ministry of Health for a Phase 2 trial of its cannabinoid therapy targeting autism spectrum disorders (ASD) and other neuropsychiatric illnesses. The double-blind trial will involve 100 patients aged 4-17, aiming to assess safety and efficacy. Expected to enroll participants in the first half of 2023, this study may lead to a treatment option for ASD and similar disorders, addressing a significant unmet medical need.
Greater Cannabis Company (OTC: GCAN) announced that Dr. Adi Aran will be featured on CNN in the documentary WEED 6: Cannabis and Autism, airing on December 19 at 9 PM ET. Dr. Aran, a leader in cannabinoid research, will discuss the therapeutic effects of cannabinoids in treating autism. This installment follows Dr. Sanjay Gupta's exploration of medical marijuana's benefits, focusing on its impact on children with autism. The special will be available on various streaming platforms, enhancing visibility for GCAN's cannabinoid therapeutics.
The Greater Cannabis Company (OTC: GCAN) has appointed Dr. Adi Aran, a leading pediatric neurologist, to advance its cannabinoid therapeutic pipeline. Dr. Aran, known for his research in cannabinoid treatments for autism, will spearhead product development and clinical studies. His experience in cannabinoid therapies is expected to enhance GCAN's strategic objectives and innovation in treatment options. According to CEO Aitan Zacharin, Dr. Aran's expertise will significantly contribute to the company's mission of providing effective medical solutions for unmet patient needs.
Greater Cannabis Company (OTC: GCAN) announced the initiation of a preclinical study for its neuropsychiatric cannabinoid therapy. This follows a license and research agreement with Shaare Zedek Scientific, led by Dr. Adi Aran. The study aims to evaluate the synergistic effects of the therapeutic in a preclinical model and is expected to conclude by Q3 2022, with interim evaluations starting Q1 2022. CEO Aitan Zacharin highlighted the unmet need in treating neuropsychiatric disorders, expressing confidence in the therapy's efficacy compared to traditional treatments.